Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health (NASDAQ:JAGX) is exploring conditional marketing authorization in Europe for crofelemer, targeting symptomatic relief of inflammatory diarrhea in long-hauler COVID-19 patients. The company plans meetings with the EMA, Swissmedic, and MHRA to facilitate this. With indications that up to 70 million people in Europe may suffer from gastrointestinal distress post-COVID-19, Jaguar aims to address this growing need. Additionally, an investor webcast is scheduled for January 14 to discuss updates and funding strategies for this initiative.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a 28-day preclinical safety and toxicity study for its plant-based drug candidate lechlemer, aimed at treating diarrhea caused by cholera, starting January 6, 2021. This study supports the upcoming Investigational New Drug (IND) application and follows prior studies in rats and shorter dog studies. The company seeks a priority review voucher from the FDA, which could enhance its market potential. Cholera remains a significant health issue, with millions of cases annually, underlining the urgency of developing effective treatments.
Jaguar Health, Inc. (NASDAQ:JAGX) has secured a $6 million non-dilutive royalty financing agreement with a secured lender. The funds will be designated for regulatory activities linked to the development pipeline, particularly for the pivotal clinical trial of Mytesi (crofelemer) aimed at cancer therapy-related diarrhea (CTD). Notably, no royalty payments are required for 18 to 24 months. CEO Lisa Conte highlighted that the growth in Mytesi's sales for HIV-related diarrhea underpins this financial opportunity. This follows a previous $6 million royalty transaction with the same lender in October 2020.
Jaguar Health announced the approval of two proposals during its Special Meeting held on December 22, 2020. The company will not implement a reverse stock split at this time. A key focus is the potential merger of Napo EU with the SPAC targeting €20-50 million investment, aimed at developing crofelemer for long-hauler syndrome gastrointestinal distress in Europe. An investor webinar is scheduled for December 23, 2020, to discuss the urgent need for regulatory approval following the emergence of a new COVID-19 strain. CEO Lisa Conte expressed optimism for the company's future.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced an investor call on December 17, 2020, to discuss recent developments following the adjournment of its Special Meeting of Stockholders.
This meeting, initially held on December 9, was postponed to December 22, allowing time to gather additional proxies. The company is working to comply with Nasdaq's bid price requirement and has secured a stay from the Listing Council.
Jaguar's efforts include expanding patient access for Mytesi, initiating a Phase 3 clinical trial for cancer therapy-related diarrhea, and considering a merger with a European SPAC.
Jaguar Health, Inc. (JAGX) has received notice from the Nasdaq Listing Council regarding its compliance with the $1.00 minimum bid price requirement. The Council will review the decision made by the Nasdaq Listing Qualifications Panel, which granted Jaguar until December 23, 2020, to remedy the bid price deficiency. The Listing Council has stayed the Panel's decision during its review. CEO Lisa Conte expressed optimism, citing efforts to improve financial prospects through expanded patient access programs and a recent $6 million capital infusion.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a fifth amendment to its accounts receivable agreement with Oasis Capital, LLC, allowing the purchase of additional accounts receivable totaling $3,810,587.04 from October 13 to December 2, 2020. This financing represents a strategic move to secure non-dilutive capital as the company sees growing sales of its Mytesi drug product.
Oasis will pay $1,619,499.49 for these receivables and charge a 5.45% fee. This indicates an increase in the financing percentage compared to previous agreements.
Jaguar Health (NASDAQ:JAGX) and Napo Pharmaceuticals plan to develop crofelemer for treating inflammatory diarrhea in long-hauler COVID-19 patients in Europe. Preliminary discussions with Swiss Growth Forum involve a SPAC merger, offering Napo a cash license fee between $2M-$10M and at least $20M for European operations. Crofelemer, an FDA-approved medication for noninfectious diarrhea in HIV/AIDS patients, aims to address chronic gastrointestinal issues post-COVID. Jaguar emphasizes the significance of early diagnosis to improve long-term recovery outcomes.
Jaguar Health, Inc. (NASDAQ:JAGX) has released a podcast interview with CEO Lisa Conte via The Wall Street Resource. The company focuses on developing plant-based, non-opioid medications for gastrointestinal issues, particularly targeting chronic diarrhea. Their flagship product, Mytesi (crofelemer), is FDA-approved for treating non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable sourcing of ingredients, highlighting ecological integrity in harvesting practices.
Jaguar Health reported third quarter 2020 financial results, showing significant growth in Mytesi product revenue totaling approximately $2.8 million, a 280% increase from $1.0 million in the same quarter of 2019. Gross sales reached approximately $6.3 million, up 332% year-over-year. Despite increased sales, the company recorded a net loss of $7.9 million, compared to $7.6 million in Q3 2019. Operating expenses rose to $8.1 million, influenced by higher general and administrative costs, including a $2.5 million trial delay fee.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
